Purchase this article with an account.
J. Arevalo, J. Fromow-Guerra, J. G. Sanchez, M. Maia, M. H. Berrocal, L. Wu, M. J. Saravia, R. A. Costa, The Pan-American Collaborative Retina Study Group(PACORES); Primary Intravitreal Bevacizumab (Avastin) for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Results of the Pan-American Collaborative Retina Study Group at 12-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2008;49(13):319.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Interventional retrospective multicenter case series in 7 centers from 6 countries. Ninety consecutive patients (112 eyes) with subfoveal CNV secondary to AMD participated. Sixty-three eyes (consecutive patients) with a mean age of 73.7 ± 7.5 years with a minimum of 12 months (mean 55.5 ± 6.2 weeks) of follow-up were included in this analysis. Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated measures analysis of variance was used to compare mean values.
The mean number of intravitreal bevacizumab injections per eye was 3.5 (range: 1 to 8). Mean baseline BCVA was 20/320, logMAR = 1.2 and mean final BCVA was 20/200, logMAR = 1.0 (p < 0.001). Central macular thickness at baseline by OCT had a mean of 389.2 µm ± 149.6 µm which was significantly reduced to a mean of 281.0 µm ± 96.1, 268.2 µm ± 82.6, 262.6µm ± 92.3 and 241.3 µm ± 76.7 at one, three, six and twelve months after initial treatment respectively (p < 0.0001). Ocular adverse events included transient arterial hypertension 2 (3.1%) patients, transient increased intraocular pressure in 2 (3.1%) eyes, endophthalmitis in 2 (3.1%) eyes, and transient hypotony in 1 eye (1.1%). No systemic adverse events were seen.
Primary intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg seems to provide stability or improvement in BCVA, OCT and FA in subfoveal CNV secondary to AMD at 12-months.
This PDF is available to Subscribers Only